Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate─a novel nonpeptide IL-6 receptor antagonist
Cited 45 time in
- Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate─a novel nonpeptide IL-6 receptor antagonist
- A Enomoto; Mun Chual Rho; A Fukami; O Hiraku; K Komiyama; M Hayashi
- Bibliographic Citation
- Biochemical and Biophysical Research Communications, vol. 323, no. 3, pp. 1096-1102
- Publication Year
- While screening for novel IL-6 inhibitors, we synthesized 20S,21-epoxy-resibufogenin-3-acetate (ERBA). ERBA dose-dependently suppressed IL-6-induced cell growth with an IC50 value of 5.3 μM and caused a parallel rightward shift of dose-response curves to IL-6. Analysis of data yields a pA2 of 5.83 and a slope of 0.99. ERBA did not affect IL-2-, IL-3-, and GCSF-dependent cell growth, or tumor necrosis factor α-induced growth suppression, nor did ERBA affect osteoclast formation induced by IL-11, leukemia inhibitory factor, and 1α,25-dihydroxyvitamin D3. Receptor assay showed that ERBA dose-dependently suppressed IL-6 binding to IL-6 receptor (IL-6R). Furthermore, no band existing at the position of IL-6R in Western blots of ERBA-treated cells when stimulated with IL-6:ERBA suppresses IL-6 activity by blocking the binding of IL-6 to IL-6R. In an experimental model of colon 26-induced cancer cachexia, ERBA markedly inhibited body weight loss. ERBA is a specific small molecule with IL-6R-antagonist activity.
- 5′DFUR; cancer cachexia; epoxy-resibufogenin; IL-6; receptor antagonist
- Appears in Collections:
- Jeonbuk Branch Institute > Immunoregulatory materials Research Center > 1. Journal Articles
- Files in This Item:
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.